Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases

A. Lleo, E. Galea, M. Sastre

Research output: Contribution to journalReview articleResearchpeer-review

91 Citations (Scopus)


During the last decade, interest has grown in the beneficial effects of non-steroidal anti-inflammatory drugs (NSAIDs) in neurodegeneration, particularly in pathologies such as Alzheimer's (AD) and Parkinson's (PD) disease. Evidence from epidemiological studies has indicated a decreased risk for AD and PD in patients with a history of chronic NSAID use. However, clinical trials with NSAIDs in AD patients have yielded conflicting results, suggesting that these drugs may be beneficial only when used as preventive therapy or in early stages of the disease. NSAIDs may also have salutary effects in other neurodegenerative diseases with an inflammatory component, such as multiple sclerosis and amyotrophic lateral sclerosis. In this review we analyze the molecular (cyclooxygenases, secretases, NF-κB, PPAR, or Rho-GTPasas) and cellular (neurons, microglia, astrocytes or endothelial cells) targets of NSAIDs that may mediate the therapeutic function of these drugs in neurodegeneration. © 2007 Birkhäuser Verlag.
Original languageEnglish
Pages (from-to)1403-1418
JournalCellular and Molecular Life Sciences
Issue number11
Publication statusPublished - 1 Jun 2007


  • Alzheimer's disease
  • Inflammation
  • Neurodegeneration
  • NSAIDs
  • PPARγ


Dive into the research topics of 'Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases'. Together they form a unique fingerprint.

Cite this